四分支即用型支架治疗复杂腹主动脉及IV型胸腹主动脉瘤关键试验的早期结果
这项多中心、非随机、前瞻性研究纳入102例复杂腹主动脉瘤(IV型胸腹主动脉瘤和肾旁动脉瘤)患者,评估GORE EXCLUDER胸腹主动脉分支支架(TAMBE)的30天结局。技术成功率达99%,30天主要不良事件发生率为6.9%,无病变相关或全因死亡,器械分支通畅率高。
要点
- TAMBE用于IV型胸腹主动脉瘤和肾旁动脉瘤,技术成功率99%。
- 30天主要不良事件发生率6.9%,无病变相关或全因死亡。
- 30天随访主动脉及内脏分支通畅率95.9%至100%。
核心结论
- TAMBE器械早期结局显示技术成功率高、30天无病变相关死亡、安全性事件发生率低。
研究设计与样本
- 多中心、非随机、前瞻性研究,纳入TAMBE器械关键试验主要研究组的102例IV型胸腹主动脉瘤和肾旁动脉瘤患者。
主要发现
- 患者平均年龄73±6.4岁(范围58-82岁),男性84例(84.2%)。
- 59例(57.8%)为IV型胸腹主动脉瘤,43例(42.2%)为肾旁动脉瘤;动脉瘤平均最大直径59.4±7.8mm。
- 技术成功99%,唯一失败原因为左肾动脉插管不成功。
- 30天主要不良事件7例(6.9%),包括呼吸衰竭2例、致残性卒中1例、需透析的新发肾衰竭2例、截瘫2例。
- 30天随访主动脉部件、肠系膜上动脉和腹腔干通畅率均为100%,左肾分支95.9%,右肾分支99.0%。
关键数值与推荐
- 技术成功定义为99%的患者达到技术成功。
- 主要不良事件按血管外科学会指南分析,30天内发生率为6.9%。
- 30天再干预9/96例(9.4%),均为轻微。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study reports the 30-day outcomes of the primary arm of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (TAMBE) pivotal trial for complex abdominal aortic aneurysm repair. METHODS: This multicenter, nonrandomized, prospective study of the TAMBE device included patients enrolled in the primary study arm of extent IV thoracoabdominal aortic aneurysms and pararenal aneurysms. Technical success and major adverse events were analyzed per the Society for Vascular Surgery guidelines. RESULTS: The 102 patients of the primary arm who underwent endovascular repair using the TAMBE device were a mean age of 73 ± 6.4 years (range, 58-82 years) and 84 (84.2%) were male. The mean body mass index was 28.3 ± 5.0 kg/m2. Fifty-nine patients (57.8%) were treated for extent IV and 43 (42.2%) pararenal aneurysms; the mean maximum diameter of the aneurysms was 59.4 ± 7.8 mm. A prophylactic cerebral spinal fluid drain was used in 10 patients (9.8%). Technical success was achieved in 99% of patients, with the single failure owing to unsuccessful cannulation of the left renal artery. Mean procedure time was 315 ± 103 minutes (range, 163-944 minutes), estimated blood loss was 300 ± 296 mL (range, 10-2000 mL), and contrast administration was 153.6 ± 73.5 mL (range, 16-420 mL). The intensive care unit length of stay was 58.7 ± 52.7 hours (range, 1-288 mL). In 28 patients (27.5%), a total of 32 additional endovascular components were deployed to manage procedural complications including aortic and target vessel dissections and injuries not related to access. Bridging stent grafts were deployed to incorporate 407 target vessels (mean 1.6/per vessel; range, 1-4). Postoperative transfusion was required in 14 patients (13.7%). Major adverse events occurred in seven patients (6.9%) through 30 days. Events included respiratory failure (n = 2), disabling stroke (n = 1), new-onset renal failure requiring dialysis (n = 2), and paraplegia (n = 2). At 30 days, there was one patient with intraoperative rupture; no severe bowel ischemia or lesion-related/all-cause mortality were reported. The Core lab-reported patency was 100% in the aortic component, superior mesenteric artery, and celiac artery, and 95.9% in the left renal and 99.0% in the right renal branch components through 30 days of follow-up. Reinterventions through 30 days were performed in 9 of 96 patients (9.4%) and were all minor. CONCLUSIONS: Early TAMBE device outcomes demonstrate a high technical success rate, no 30-day lesion-related mortality, and a low rate of safety events within 30 days of the index procedure.
引用
- Farber MA, Matsumura JS, Han S, et al. Early outcomes from the pivotal trial of a four-branch off-the shelf solution to treat complex abdominal and type IV thoracoabdominal aortic aneurysms. J Vasc Surg. 2024. PMID: 38904579. doi:10.1016/j.jvs.2024.05.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。